Cargando…
Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies
PrabotulinumtoxinA is a 900-kDa botulinum toxin Type A produced by Clostridium botulinum. OBJECTIVE: To investigate the efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines. MATERIALS AND METHODS: Adult subjects (n = 330 in EV-001; n = 324 in EV-002) with moderate to severe...
Autores principales: | Beer, Kenneth R., Shamban, Ava Theresa, Avelar, Rui L., Gross, John E., Jonker, Anneke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819028/ https://www.ncbi.nlm.nih.gov/pubmed/30893162 http://dx.doi.org/10.1097/DSS.0000000000001903 |
Ejemplares similares
-
PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data
por: Ogilvie, Patricia, et al.
Publicado: (2022) -
PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data
por: Taylor, Susan C., et al.
Publicado: (2021) -
The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II
Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar
Lines in Adult Patients
por: Kaufman-Janette, Joely, et al.
Publicado: (2021) -
Corrigendum to: The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Kaufman-Janette, Joely, et al.
Publicado: (2021) -
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data
por: Solish, Nowell, et al.
Publicado: (2022)